Optimal management of multiple sclerosis during pregnancy: current perspectives
- PMID: 32669905
- PMCID: PMC7337198
- DOI: 10.2147/DNND.S48618
Optimal management of multiple sclerosis during pregnancy: current perspectives
Abstract
Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous system. It frequently affects females in their reproductive phase of life. Therefore, family planning, pregnancy, and breastfeeding are important issues in the management of MS, particularly with respect to counseling and drug treatment. This paper reviews currently available data on the outcome of pregnancies in MS patients and the influence of pregnancy on the course of the disease. We give an update on the use of various disease-modifying MS drugs during pregnancy and breastfeeding. In addition to established therapies such as interferon-β, glatiramer acetate, natalizumab, and fingolimod, we also discuss the state of knowledge about new agents such as dimethyl fumarate, teriflunomide, and alemtuzumab in the context of pregnancy and breastfeeding.
Keywords: disease-modifying therapy; lactation; multiple sclerosis; pregnancy.
© 2014 Borisow et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
References
-
- Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648): 1502–1517. - PubMed
-
- Chancellor AM, Addidle M, Dawson K. Multiple sclerosis is more prevalent in northern New Zealand than previously reported. Intern Med J. 2003;33(3):79–83. - PubMed
-
- Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5(11):932–936. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
